<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antitrypanosomal drugs for treatment of Chagas disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antitrypanosomal drugs for treatment of Chagas disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antitrypanosomal drugs for treatment of Chagas disease</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup> <colgroup width="60%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Drug</td> <td class="subtitle1">Age group</td> <td class="subtitle1">Dosing regimen</td> </tr> <tr class="divider_top"> <td class="divider_bottom" rowspan="2">Benznidazole</td> <td>2 to 12 years</td> <td>5 to 8 mg/kg per day orally in 2 divided doses for 60 days</td> </tr> <tr class="divider_bottom"> <td>&gt;12 years*</td> <td>5 mg/kg per day orally in 2 divided doses for 60 days</td> </tr> <tr> <td rowspan="3">Nifurtimox<sup>¶</sup></td> <td rowspan="2">Birth to 17 years</td> <td>Body weight 2.5 to 40 kg: 10 to 20 mg/kg/day in 3 divided doses for 60 days</td> </tr> <tr> <td>Body weight 41 kg or more: 8 to 10 mg/kg/day in 3 divided doses for 60 days</td> </tr> <tr> <td>≥18 years<sup>Δ</sup></td> <td>8 to 10 mg/kg/day in 3 divided doses for 60 to 90 days</td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>For additional notes regarding use, adverse effects, and availability, refer to the UpToDate topic on antitrypanosomal drug therapy.</p>
    
    Similar recommendations are included in the 2015 Brazilian Consensus on Chagas Disease, which recommend for adults 5 mg/kg of benznidazole per day in two or three divided doses for 60 days or 10 mg/kg of nifurtimox per day in three divided doses for 60 days; for children, these guidelines recommend 5 to 10 mg/kg of benznidazole for 60 days or 15 mg/kg of nifurtimox for 60 to 90 days.<sup>[1]</sup></div><div class="graphic_footnotes"><p>* Use in patients 12 years or older is off-label. Some investigators treat adults with 300 mg per day for 60 days, regardless of body weight,<sup>[2]</sup> whereas others use an upper limit of 300 mg per day but prolong treatment to complete the total dose corresponding to 5 mg per kilogram per day for 60 days.<sup>[1,3]</sup></p>
<p>¶ There are no published recommendations regarding an upper dose limit for nifurtimox. The standard nifurtimox dosing schedule for human African trypanosomiasis is 15 mg per kilogram per day for 10 days (in combination with efluornithine).<sup>[4]</sup> Dosing regimens of up to 30 mg per kilogram per day in multiple 21-day cycles have been used in trials for neuroblastoma involving children.<sup>[5]</sup> Some adverse effects appear to be related to length of treatment rather than daily dose; regimens from 60 days to 120 days have been used.<sup>[6,7]</sup> Because of the side effects, only 50 to 60% of adult patients complete the entire treatment course.<sup>[6]</sup></p>
    
    Δ Use in adults 18 years or older is off-label.</div><div class="graphic_reference">References:
    <ol>
<li>Dias JC, Ramos AN Jr, Gontijo ED, et al. 2<sup>nd</sup> Brazilian Consensus on Chagas Disease, 2015. Rev Soc Bras Med Trop 2016; 49Suppl 1:3..</li>
<li>Molina I, Gómez i Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 2014; 370:1899.</li>
<li>Rassi A Jr, Dias JC, Marin-Neto JA, Rassi A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart 2009; 95:524.</li>
<li>Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial Lancet 2009; 374:56.</li>
<li>Saulnier Sholler GL, Bergendahl GM, Brard L, et al. A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma J Pediatr Hematol Oncol 2011; 33:25.</li>
<li>Jackson Y, Alirol E, Getaz L, et al. Tolerance and safety of nifurtimox in patients with chronic Chagas disease. Clin Infect Dis 2010; 51:e69.</li>
<li>Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection: preliminary report. Arzneimittelforschung 1972; 22:1635.</li>
</ol></div><div id="graphicVersion">Graphic 54443 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
